CDK7 Inhibition is Effective in all the Subtypes of Breast Cancer: Determinants of Response and Synergy with EGFR Inhibition

CDK7 Inhibition is Effective in all the Subtypes of Breast Cancer: Determinants of Response and Synergy with EGFR Inhibition

CDK7, a transcriptional cyclin-dependent kinase, is emerging as a novel cancer target. Triple-negative breast cancers (TNBC) but not estrogen receptor-positive (ER+) breast cancers have been reported to be uniquely sensitive to the CDK7 inhibitor THZ1 due to the inhibition of a cluster of TNBC-speci...

Full description

Bibliographic Details
Main Authors: Martina S.J. McDermott, Amanda C. Sharko, Jessica Munie, Susannah Kassler, Theresa Melendez, Chang-uk Lim, Eugenia V. Broude
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Cells
Subjects:
cdk7
breast cancer
transcription
cited2
egfr
Online Access:https://www.mdpi.com/2073-4409/9/3/638

Internet

https://www.mdpi.com/2073-4409/9/3/638

Similar Items